Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Trevi Therapeutics, Inc. (TRVI : NSDQ)

• Company Description    Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut. Number of Employees: 24

• Price / Volume Information    Yesterday's Closing Price: $2.22 Daily Weekly Monthly 20 Day Moving Average: 193,212 shares Shares Outstanding: 38.69 (millions) Market Capitalization: $85.88 (millions) Beta: 0.31 52 Week High: $3.73 52 Week Low: $0.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.13% -24.68% 12 Week 353.06% 398.11% Year To Date 183.82% 246.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 195 CHURCH STREET 14TH FLOOR - NEW HAVEN,CT 06510 USA ph: 203-304-2499 fax: - chris.seiter@trevitherapeutics.com http://www.trevitherapeutics.com

• General Corporate Information    Officers Jennifer Good - President and Chief Executive Officer; Director David Meeker - Chairman Lisa Delfini - Chief Financial Officer Christopher Galletta - Controller James V. Cassella - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89532M101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 38.69 Most Recent Split Date: (:1) Beta: 0.31 Market Capitalization: $85.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.21 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 44.19% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -232.28 12/31/21 - -194.29 09/30/21 - -174.53 ROA 03/31/22 - -94.26 12/31/21 - -89.27 09/30/21 - -86.96 Current Ratio 03/31/22 - 2.32 12/31/21 - 2.98 09/30/21 - 3.10 Quick Ratio 03/31/22 - 2.32 12/31/21 - 2.98 09/30/21 - 3.10 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.27 12/31/21 - 0.66 09/30/21 - 0.47 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.67 12/31/21 - 0.51 09/30/21 - 0.90 Debt-to-Capital 03/31/22 - 40.28 12/31/21 - 33.63 09/30/21 - 47.38

Powered by Zacks Investment Research ©